Skip to content

Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology. APPART trial

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500933-10-00
Acronym
RC31/21/0337
Enrollment
1164
Registered
2022-10-18
Start date
2023-08-02
Completion date
Unknown
Last updated
2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia during pregnancy

Brief summary

Occurrence of preterm (<37 weeks of gestation) preeclampsia (binary variable yes/no).

Detailed description

Occurrence of spontaneous and total preterm birth (defined by delivery at <34 weeks of gestation), Occurrence of spontaneous and total preterm birth (defined by delivery at <37weeks of gestation), Occurrence of term (≥37 weeks) preeclampsia., Occurrence of preeclampsia before 34 weeks of gestation., Occurrence of cesarean delivery., Occurrence of postpartum hemorrhage (>500ml), Occurrence of placental abruption, Occurrence of stillbirth, Birthweight, Occurrence of severe maternal morbidity (occurrence of at least one of the following: severe postpartum hemorrhage (>1000ml), treatment of postpartum hemorrhage by embolization, vascular ligature, hysterectomy, secondary post-partum hemorrhage, pulmonary embolism, cardiovascular complications, neuropsychological complications, maternal transfer to intensive care unit, maternal death)., Neonatal death (before 28 days of life) or occurrence of neonatal complications including intraventricular hemorrhage grade II or above, sepsis with confirmed bacteremia in cultures, anemia requiring blood transfusion, respiratory distress syndrome treated with surfactant and ventilation, necrotizing enterocolitis requiring surgery, intensive care unit admission, ventilation with positive airway pressure or intubation., Occurrence of maternal expected adverse events (any bleeding, headache, nausea, skin rash, dyspepsia, abdominal pain) recorded from randomization and until hospital discharge after delivery, Adherence to the treatment (by counting the pills at each visit and by using a diary or an application)., Number of consumed resources and unit costs of hospitalizations, consultations, medical acts, medication, medical devices and transportation., Incremental cost-effectiveness from the collective perspective expressed in terms of cost per number of preterm pre-eclampsia avoided from the initiation of aspirin or placebo 1 months after the delivery., Occupation, level of income and level of education will be recorded to test the impact of socioeconomic characteristics on the cost of care and efficiency.

Interventions

DRUGACETYLSALICYLIC ACID
DRUGmicrocrystalline cellulose with the same size and colour as the active drug

Sponsors

Centre Hospitalier Universitaire De Toulouse
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Occurrence of preterm (<37 weeks of gestation) preeclampsia (binary variable yes/no).

Secondary

MeasureTime frame
Occurrence of spontaneous and total preterm birth (defined by delivery at <34 weeks of gestation), Occurrence of spontaneous and total preterm birth (defined by delivery at <37weeks of gestation), Occurrence of term (≥37 weeks) preeclampsia., Occurrence of preeclampsia before 34 weeks of gestation., Occurrence of cesarean delivery., Occurrence of postpartum hemorrhage (>500ml), Occurrence of placental abruption, Occurrence of stillbirth, Birthweight, Occurrence of severe maternal morbidity (occurrence of at least one of the following: severe postpartum hemorrhage (>1000ml), treatment of postpartum hemorrhage by embolization, vascular ligature, hysterectomy, secondary post-partum hemorrhage, pulmonary embolism, cardiovascular complications, neuropsychological complications, maternal transfer to intensive care unit, maternal death)., Neonatal death (before 28 days of life) or occurrence of neonatal complications including intraventricular hemorrhage grade II or above, sepsis with confirm

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026